Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$203.68 USD

203.68
4,493,768

+0.13 (0.06%)

Updated Nov 4, 2024 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus

LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.

Santanu Roy  headshot

5 Stocks That Recently Announced Dividend Hikes

Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.

Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.74% and 1.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates

Pfizer (PFE) delivered earnings and revenue surprises of 65.62% and 16.53%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?

Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.

Kinjel Shah headshot

Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?

Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.

Sundeep Ganoria  headshot

Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.

Curious about AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for AbbVie (ABBV), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

AbbVie (ABBV) Outperforms Broader Market: What You Need to Know

In the closing of the recent trading day, AbbVie (ABBV) stood at $189.65, denoting a +0.94% change from the preceding trading day.

Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Is Pfizer's Attractive Valuation Enough to Invest in the Stock?

PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.

The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q3 Earnings, FDA Nod to Some New Drugs

J&J tops third-quarter earnings and sales estimates. FDA approves new drugs of Pfizer, Roche and AbbVie.

The Zacks Analyst Blog Highlights AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market

AbbVie, Automatic Data Processing, Analog Devices, Taylor Devices and Village Super Market are part of the Zacks top Analyst Blog.

AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev

With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.

AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know

AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.

Mark Vickery headshot

Top Stock Reports for AbbVie, ADP & Analog Devices

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data Processing, Inc. (ADP) and Analog Devices, Inc. (ADI), as well as two micro-cap stocks Taylor Devices, Inc. (TAYD) and Village Super Market, Inc. (VLGEA).

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

Smart Beta ETF report for DHS

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

AbbVie (ABBV) Stock Moves -0.21%: What You Should Know

AbbVie (ABBV) reachead $194.35 at the closing of the latest trading day, reflecting a -0.21% change compared to its last close.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP